FDA Approves High-Dose Wegovy 7.2mg for Obesity in 2026

The FDA approved high-dose semaglutide 7.2mg (Wegovy) for obesity, showing 18.7% mean weight loss in Phase 3 trials amid new Trump administration drug pricing agreements.